Prostate Ⅰ In The Treatment Of Type Ⅲ Prostatitis (Damp Heat Stasis Syndrome) Clinical Study

Objiective:By observing the prostate I number treat type Ⅲ prostatitis (hot and damp stasis resistance syndrome) clinical curative effect, a preliminary exploration of the prostate I number mechanism, the efficacy of type Ⅲ prostatitis type validation prostate I number of Ⅲ prostatitis (hot and damp stasis resistance) efficacy and safety of type for Ⅲ prostatitis clinical research opens a new train of thought, to provide theoretical and clinical basis for clinical widely used.Methods:Choose between April2013-2014in March due to type Ⅲ prostatitis from Jiangsu Provincial Hospital (Nanjing University of Traditional Chinese Medicine,Affiliated Hospital) were male ward or outpatient clinic were randomly divided into treatment group and control group30cases in the general treatment given on the basis of the treatment group received oral prostate No. Ⅰ200m1,2times/day; Qianliebeixi capsule control group received capsules6,3times/day; course of4weeks. Before and after treatment, respectively, to the U.S. National Institutes of Health chronic prostatitis symptom score (NIH-CPSI), chronic prostatitis (hot and damp stasis resistance syndrome) symptom scores, prostatic fluid (EPS) in the WBC (white blood cell) count and the number of lecithin, serum cytokines such as:interleukin-8(IL-8), tumor necrosis factor (TNF-α) were evaluated severity and efficacy of prostatitis.Results:1.Prostate I number with Qianliebeixi capsule can effectively treat type Ⅲ prostatitis (hot and damp stasis resistance certificate).2.In accordance with the western medicine curative effect evaluation standard, the treatment group and control group in clinical effectiveness were83.33%and60.00%respectively, according to Chinese medicine efficacy evaluation standards, two groups of clinical effectiveness were80.00%and63.33%respectively, the test efficiency between the two groups have significant difference (P<0.05).3.Prostate I number, the treatment group to pain, quality of life, in the prostatic secretion (EPS) the WBC (WBC) count and number of lecithin corpuscle, cytokines, interleukin-8, tumor necrosis factor), etc. The improvement on the quantitative, xi capsule in the control group were superior to lead times, the statistical significant difference (P<0.05), and in urination and interleukin-6quantitative improvements, such as the statistics, there was no significant difference between the two groups (P>0.05).Conclusion: Prostate I number on type Ⅲ prostatitis (hot and damp stasis resistance syndrome) have significant therapeutic effect, can significantly improve the clinical symptoms, improve quality of life, clinically proven prostate No. Ⅰ safe, effective, no significant adverse reactions, is worthy of promotion.